Cytek Biosciences, Inc.

Industrials
Biotechnology: Laboratory Analytical Instruments
www.cytekbio.com

Earnings Score
Moat Score
Safety Score

Market Cap $881.76M
PE -87
Debt $1.24M
Cash $162.30M
EV $720.69M
FCF $28.76M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$10.16M
EBIT	-$11.91M
ROE	-3%
ROA	-2%
FCF	$28.76M
Equity	$385.46M
Growth Stability	-639%
PE	-86.79
PEG	1.92K
PB	2.29
P/FCF	30.66
P/S	4.38
Price/Cash	0.18
Debt/Equity	0
Debt/FCF	0.04
Net Margins	-11%
Gross Margins	55%
Op. Margins	-6%
Earnings CAGR	-0%
Sales Growth YoY	7%
Sales Growth QoQ	10%
Sales CAGR	19%
FCF CAGR	5%
Equity CAGR	-1%
Earnings Stability	-0.76
Earnings Growth YoY	-115%
Earnings Growth QoQ	-109%

Earnings CAGR 5Y	-0%
Sales CAGR 5Y	19%
FCF CAGR 5Y	5%
Equity CAGR 5Y	-1%
Earnings CAGR 3Y	18%
Sales CAGR 3Y	18%
FCF CAGR 3Y	94%
Equity CAGR 3Y	-2%
Market Cap	$881.76M
Revenue	$201.21M
Assets	$491.23M
Total Debt	$1.24M
Cash	$162.30M
Shares Outstanding	129.77M
EV	720.69M
Earnings Score	6%
Moat Score	8%
Safety Score	67%
Final Score	27%
Working Capital	327.39M
Current Ratio	6.21
Gross Profit	$110.50M
Shares Growth 3y	1%
Equity Growth QoQ	-1%
Equity Growth YoY	-7%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.

SEC Filings

Direct access to Cytek Biosciences, Inc. (CTKB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cytek Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cytek Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -0%

Stability -76%

loading chart...

Cytek Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cytek Biosciences, Inc..

Years

Calculation mode

= $413M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$29M	$30M	$32M	$34M	$35M	$37M	$39M	$41M	$43M	$46M	$48M	$480M
DCF		$28M	$26M	$25M	$24M	$23M	$22M	$21M	$20M	$19M	$19M	$185M
Value	$413M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	3%	0%	2%	-6%	-11%
ROA	-	2%	0%	-3%	-2%
ROE	-	0%	1%	-3%	-3%

Bad Net Margins (-10.95%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	0	-0.1	2.6	0.04
Debt over Equity	-	0	0.01	0	0
Growth Stability	-	-	-	-639%	-639%

Good Debt/FCF ratio (0.04)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-639%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	38%	28%	18%	19%
Earnings YoY growth	-	-100%	-	-589%	-0%
Equity YoY growth	-	-3K%	5%	-8%	-1%
FCF YoY growth	-	-98%	-8K%	-103%	5%